open access

Vol 3, No 1 (2018)
REVIEW
Published online: 2018-07-20
Get Citation

Ranibizumab in Diabetic Macular Edema; Level 1 and Level 2 Studies Findings

Arief Kartasasmita, Elvis Elvioza, Habibah S Muhiddin
DOI: 10.5603/OJ.2018.0028
·
Ophthalmology J 2018;3(1):14-20.

open access

Vol 3, No 1 (2018)
REVIEW
Published online: 2018-07-20

Abstract

INTRODUCTION. Ranibizumab is an anti-VEGF antibody widely used in DME treatment.

MATERIALS AND METHODS. We conducted a literature search using the keywords “diabetes”, “diabetic retinopathy”, “diabetic macular edema”, “pathophysiology”, “VEGF”, “treatment”, “anti-VEGF”, “ranibizumab”, “lucentis” with limitation of English language. The articles published between 2006–2016 years and we reviewed level I and level II studies.

RESULTS. Review from several level I and level II intravitreal ranibizumab injection studies suggests that ranibizumab is an anti-VEGF that effectively used in DME treatment. Comparison with other anti-VEGF also suggest that ranibizumab is effective for DME patients for over 2 years treatment.

CONCLUSIONS. Ranibizumab monotherapy and/or combination with laser is safe and effective for DME patients for over 2 years treatment.

Abstract

INTRODUCTION. Ranibizumab is an anti-VEGF antibody widely used in DME treatment.

MATERIALS AND METHODS. We conducted a literature search using the keywords “diabetes”, “diabetic retinopathy”, “diabetic macular edema”, “pathophysiology”, “VEGF”, “treatment”, “anti-VEGF”, “ranibizumab”, “lucentis” with limitation of English language. The articles published between 2006–2016 years and we reviewed level I and level II studies.

RESULTS. Review from several level I and level II intravitreal ranibizumab injection studies suggests that ranibizumab is an anti-VEGF that effectively used in DME treatment. Comparison with other anti-VEGF also suggest that ranibizumab is effective for DME patients for over 2 years treatment.

CONCLUSIONS. Ranibizumab monotherapy and/or combination with laser is safe and effective for DME patients for over 2 years treatment.

Get Citation

Keywords

diabetic macular edema, anti VEGF, ranibizumab

About this article
Title

Ranibizumab in Diabetic Macular Edema; Level 1 and Level 2 Studies Findings

Journal

Ophthalmology Journal

Issue

Vol 3, No 1 (2018)

Pages

14-20

Published online

2018-07-20

DOI

10.5603/OJ.2018.0028

Bibliographic record

Ophthalmology J 2018;3(1):14-20.

Keywords

diabetic macular edema
anti VEGF
ranibizumab

Authors

Arief Kartasasmita
Elvis Elvioza
Habibah S Muhiddin

References (25)
  1. Cho NH, et al. IDF Diabetes Atlas, International Diabetes Federation (IDF), Brussels, Belgium, 7th edition. 2015.
  2. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2014; 37(suppl1): 81–90.
  3. Cheung N, et al. et al.. Diabetic Retinopathy Lancet. 2010; 376: 124–36.
  4. Diabetic Retinopathy Preferred Practice Pattern® (“PPP”) guidelines. Updated 2016. https://www.aao.org/preferred-practice-pattern/diabetic-retinopathy-ppp-updated-2016. (Accessed on 14th Aug).
  5. Yau JWY, Rogers SL, Kawasaki R, et al. Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012; 35(3): 556–564.
  6. Lang GE. Diabetic macular edema. Ophthalmologica. 2012; 227 Suppl 1: 21–29.
  7. Scholl S, Augustin A, Loewenstein A, et al. Pathophysiology of macular edema. Ophthalmologica. 2010; 224 Suppl 1: 8–15.
  8. Nguyen QD, Tatlipinar S, Shah SM, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol. 2006; 142(6): 961–969.
  9. https://www.elsevier.com/__data/promis_misc/623124los.pdf. (Accessed on 28 Aug 2017).
  10. Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006; 26(8): 859–870.
  11. Chun DW, Heier JS, Topping TM, et al. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology. 2006; 113(10): 1706–1712.
  12. EDWARDS P. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Acta Ophthalmologica. 2010; 88: 0–0.
  13. Elman MJ, Bressler NM, Qin H, et al. Diabetic Retinopathy Clinical Research Network. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011; 118(4): 609–614.
  14. Sivaprasad S, Regnier SA, Fajnkuchen F, et al. RESTORE study group. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011; 118(4): 615–625.
  15. Nguyen QD, Brown DM, Marcus DM, et al. RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012; 119(4): 789–801.
  16. Wells JA, Glassman AR, Ayala AR, et al. Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015; 372(13): 1193–1203.
  17. Wells J, Glassman A, Ayala A, et al. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. Ophthalmology. 2016; 123(6): 1351–1359.
  18. Elman MJ, Qin H, Aiello LP, et al. Diabetic Retinopathy Clinical Research Network. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology. 2012; 119(11): 2312–2318.
  19. Elman MJ, Ayala A, Bressler NM, et al. Diabetic Retinopathy Clinical Research Network. Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology. 2015; 122(2): 375–381.
  20. Lang GE, Berta A, Eldem BM, et al. RESTORE Extension Study Group. Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study. Ophthalmology. 2013; 120(10): 2004–2012.
  21. Schmidt-Erfurth U, Lang GE, Holz FG, et al. RESTORE Extension Study Group. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology. 2014; 121(5): 1045–1053.
  22. Brown D, Nguyen Q, Marcus D, et al. Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III Trials. Ophthalmology. 2013; 120(10): 2013–2022.
  23. Massin P, et al. Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study). Diabetes Care. 2010; 33: 2399–2405.
  24. Nguyen QD, Shah SM, Heier JS, et al. READ-2 Study Group. Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study. Ophthalmology. 2009; 116(11): 2175–21781.e1.
  25. Nguyen QD, Shah SM, Khwaja AA, et al. READ-2 Study Group. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology. 2010; 117(11): 2146–2151.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

VM Media sp. z o.o. VM Group sp.k., Grupa Via Medica, 73 Świętokrzyska St., 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl